Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins

Current Drug Targets

Volumn 14, Issue 3, 2013, Pages 287-324

  Kucukguven, Arda ^a   Khalil, Raouf A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Chronic venous insufficiency disease; Endothelium; Extracellular matrix; MMP; TIMP; Vascular smooth muscle

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL) CHROMONE; 2 [[(4 PHENOXYPHENYL) SULFONYL] METHYL] THIIRANE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL) IMIDAZOLE; BATIMASTAT; COUMARIN; DAFLON; DOXYCYCLINE; GELATINASE A; GELATINASE B; GINKGO BILOBA EXTRACT; GINKOR FORT; HEPTAMINOL; IBERIOTOXIN; ILOMASTAT; INCYCLINIDE; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 19; MATRIX METALLOPROTEINASE 20; MATRIX METALLOPROTEINASE 26; MONOXERUTIN; OXERUTIN; PENTOXIFYLLINE; PLACEBO; PROSTAGLANDIN E1; TACROLIMUS; TROXERUTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOOSTEOHYPERTROPHY SYNDROME; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; BLOOD VESSEL PERMEABILITY; CARDIOVASCULAR DISEASE; CELL DAMAGE; CELL PROLIFERATION; CHRONIC VEIN INSUFFICIENCY; DECUBITUS; DISEASE ASSOCIATION; DISEASE COURSE; EHLERS DANLOS SYNDROME; EXTRACELLULAR MATRIX; FIBROSIS; GENE MUTATION; HUMAN; HYDROSTATIC PRESSURE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LEG ULCER; MICROARRAY ANALYSIS; NEUROPROTECTION; NONHUMAN; OSTEOARTHRITIS; PHAGOCYTOSIS; PREVALENCE; PROSTATE CANCER; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RHEUMATOID ARTHRITIS; RISK FACTOR; SCLEROTHERAPY; THROMBOPHLEBITIS; TUMOR GROWTH; VARICOSIS; VEIN DILATATION; VEIN THROMBOSIS; VENA CAVA FILTER; WOUND HEALING;

EID: 84876732671     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450111314030003     Document Type: Article

References (463)

1. Raffetto JD, Khalil RA. Mechanisms of varicose vein formation: valve dysfunction and wall dilation. Phlebology 2008; 23(2): 85-98.
2. Bergan JJ, Schmid-Schonbein GW, Smith PD, Nicolaides AN, Boisseau MR, Eklof B. Chronic venous disease. N Engl J Med 2006; 355(5): 488-98.
3. Zhou D, Lee HS, Villarreal F, et al. Differential MMP-2 activity of ligament cells under mechanical stretch injury: an in vitro study on human ACL and MCL fibroblasts. J Orthop Res 2005; 23(4): 949-57.
4. Milkiewicz M, Haas TL. Effect of mechanical stretch on HIF-1{alpha} and MMP-2 expression in capillaries isolated from overloaded skeletal muscles: laser capture microdissection study. Am J Physiol Heart Circ Physiol 2005; 289(3): H1315-20.
5. Schmid-Schonbein GW, Takase S, Bergan JJ. New advances in the understanding of the pathophysiology of chronic venous insufficiency. Angiology 2001; 52 Suppl 1: S27-34.
6. Asanuma K, Magid R, Johnson C, Nerem RM, Galis ZS. Uniaxial strain upregulates matrix-degrading enzymes produced by human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2003; 284(5): H1778-84.
7. Raffetto JD, Ross RL, Khalil RA. Matrix metalloproteinase 2-induced venous dilation via hyperpolarization and activation of K+ channels: relevance to varicose vein formation. J Vasc Surg 2007; 45(2): 373-80.
8. Raffetto JD, Qiao X, Koledova VV, Khalil RA. Prolonged increases in vein wall tension increase matrix metalloproteinases and decrease constriction in rat vena cava: Potential implications in varicose veins. J Vasc Surg 2008; 48(2): 447-56.
9. Raffetto JD, Barros YV, Wells AK, Khalil RA. MMP-2 induced vein relaxation via inhibition of [Ca2+]e-dependent mechanisms of venous smooth muscle contraction. Role of RGD peptides. J Surg Res 2010; 159(2): 755-64.
10. Beebe-Dimmer JL, Pfeifer JR, Engle JS, Schottenfeld D. The epidemiology of chronic venous insufficiency and varicose veins. Ann Epidemiol 2005; 15(3): 175-84.
11. McLafferty RB, Lohr JM, Caprini JA, et al. Results of the national pilot screening program for venous disease by the American Venous Forum. J Vasc Surg 2007; 45(1): 142-8.
12. Eklof B, Rutherford RB, Bergan JJ, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg 2004; 40(6): 1248-52.
13. Scott TE, LaMorte WW, Gorin DR, Menzoian JO. Risk factors for chronic venous insufficiency: a dual case-control study. J Vasc Surg 1995; 22(5): 622-8.
14. Jawien A. The influence of environmental factors in chronic venous insufficiency. Angiology 2003; 54 Suppl 1: S19-31.
15. Lacroix P, Aboyans V, Preux PM, Houles MB, Laskar M. Epidemiology of venous insufficiency in an occupational population. Int Angiol 2003; 22(2): 172-6.
16. Lee AJ, Evans CJ, Allan PL, Ruckley CV, Fowkes FG. Lifestyle factors and the risk of varicose veins: Edinburgh Vein Study. J Clin Epidemiol 2003; 56(2): 171-9.
17. Christopoulos D, Nicolaides AN, Szendro G. Venous reflux: quantification and correlation with the clinical severity of chronic venous disease. Br J Surg 1988; 75(4): 352-6.
18. Zamboni P, Scapoli G, Lanzara V, et al. Serum iron and matrix metalloproteinase-9 variations in limbs affected by chronic venous disease and venous leg ulcers. Dermatol Surg 2005; 31(6): 644-9; discussion 9.
19. Zamboni P, Izzo M, Tognazzo S, et al. The overlapping of local iron overload and HFE mutation in venous leg ulcer pathogenesis. Free Radic Biol Med 2006; 40(10): 1869-73.
20. Zamboni P, De Mattei M, Ongaro A, et al. Factor XIII contrasts the effects of metalloproteinases in human dermal fibroblast cultured cells. Vasc Endovascular Surg 2004; 38(5): 431-8.
21. Zamboni P, Tognazzo S, Izzo M, et al. Hemochromatosis C282Y gene mutation increases the risk of venous leg ulceration. J Vasc Surg 2005; 42(2): 309-14.
22. Tognazzo S, Gemmati D, Palazzo A, et al. Prognostic role of factor XIII gene variants in nonhealing venous leg ulcers. J Vasc Surg 2006; 44(4): 815-9.
23. Gemmati D, Tognazzo S, Catozzi L, et al. Influence of gene polymorphisms in ulcer healing process after superficial venous surgery. J Vasc Surg 2006; 44(3): 554-62.
24. Noel AA, Gloviczki P, Cherry KJ, Jr., Rooke TW, Stanson AW, Driscoll DJ. Surgical treatment of venous malformations in Klippel-Trenaunay syndrome. J Vasc Surg 2000; 32(5): 840-7.
25. Delis KT, Gloviczki P, Wennberg PW, Rooke TW, Driscoll DJ. Hemodynamic impairment, venous segmental disease, and clinical severity scoring in limbs with Klippel-Trenaunay syndrome. J Vasc Surg 2007; 45(3): 561-7.
26. Ng MY, Andrew T, Spector TD, Jeffery S. Linkage to the FOXC2 region of chromosome 16 for varicose veins in otherwise healthy, unselected sibling pairs. J Med Genet 2005; 42(3): 235-9.
27. Brice G, Mansour S, Bell R, et al. Analysis of the phenotypic abnormalities in lymphoedema-distichiasis syndrome in 74 patients with FOXC2 mutations or linkage to 16q24. J Med Genet 2002; 39(7): 478-83.
28. Serra R, Buffone G, de Franciscis A, et al. A genetic study of chronic venous insufficiency. Ann Vasc Surg 2012; 26(5): 636-42.
29. Saiki S, Sakai K, Saiki M, et al. Varicose veins associated with CADASIL result from a novel mutation in the Notch3 gene. Neurology 2006; 67(2): 337-9.
30. Lee S, Lee W, Choe Y, et al. Gene expression profiles in varicose veins using complementary DNA microarray. Dermatol Surg 2005; 31(4): 391-5.
31. Dalal A, Phadke SR. Hemihyperplasia with Ehlers-Danlos syndrome like skin changes. Clin Dysmorphol 2005; 14(4): 207-8.
32. Badauy CM, Gomes SS, Sant'Ana Filho M, Chies JA. Ehlers-Danlos syndrome (EDS) type IV: review of the literature. Clin Oral Investig 2007; 11(3): 183-7.
33. Xu HM, Zhao Y, Zhang XM, Zhu T, Fu WG. Polymorphisms in MMP-9 and TIMP-2 in Chinese patients with varicose veins. J Surg Res 2011; 168(1): e143-8.
34. Clarke GH, Vasdekis SN, Hobbs JT, Nicolaides AN. Venous wall function in the pathogenesis of varicose veins. Surgery 1992; 111(4): 402-8.
35. Reagan B, Folse R. Lower limb venous dynamics in normal persons and children of patients with varicose veins. Surg Gynecol Obstet 1971; 132(1): 15-8.
36. Zsoter T, Cronin RF. Venous distensibility in patients with varicose veins. Can Med Assoc J 1966; 94(25): 1293-7.
37. Sansilvestri-Morel P, Rupin A, Badier-Commander C, et al. Imbalance in the synthesis of collagen type I and collagen type III in smooth muscle cells derived from human varicose veins. J Vasc Res 2001; 38(6): 560-8.
38. Miskulin M, Dalgleish R, Kluve-Beckerman B, et al. Human type III collagen gene expression is coordinately modulated with the type I collagen genes during fibroblast growth. Biochemistry 1986; 25(6): 1408-13.
39. Sansilvestri-Morel P, Rupin A, Badier-Commander C, Fabiani JN, Verbeuren TJ. Chronic venous insufficiency: dysregulation of collagen synthesis. Angiology 2003; 54 Suppl 1: S13-8.
40. Brand FN, Dannenberg AL, Abbott RD, Kannel WB. The epidemiology of varicose veins: the Framingham Study. Am J Prev Med 1988; 4(2): 96-101.
41. Bradbury A, Evans C, Allan P, Lee A, Ruckley CV, Fowkes FG. What are the symptoms of varicose veins? Edinburgh vein study cross sectional population survey. BMJ 1999; 318(7180): 353-6.
42. Evans CJ, Fowkes FG, Ruckley CV, Lee AJ. Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study. J Epidemiol Community Health 1999; 53(3): 149-53.
43. Ruckley CV, Evans CJ, Allan PL, Lee AJ, Fowkes FG. Chronic venous insufficiency: clinical and duplex correlations. The Edinburgh Vein Study of venous disorders in the general population. J Vasc Surg 2002; 36(3): 520-5.
44. Raffetto JD, Qiao X, Beauregard KG, Khalil RA. Estrogen receptor-mediated enhancement of venous relaxation in female rat: implications in sex-related differences in varicose veins. J Vasc Surg 2010; 51(4): 972-81.
45. Challis JRG, Matthews SG, Gibb W, Lye SJ. Endocrine and paracrine regulation of birth at term and preterm. Endocr Rev 2000; 21(5): 514-50.
46. Bernstein IM, Ziegler W, Badger GJ. Plasma volume expansion in early pregnancy. Obstet Gynecol 2001; 97(5 Pt 1): 669-72.
47. Chapman AB, Abraham WT, Zamudio S, et al. Temporal relationships between hormonal and hemodynamic changes in early human pregnancy. Kidney Int 1998; 54(6): 2056-63.
48. Stansby G. Women, pregnancy, and varicose veins. Lancet 2000; 355(9210): 1117-8.
49. Mekky S, Schilling RS, Walford J. Varicose veins in women cotton workers. An epidemiological study in England and Egypt. Br Med J 1969; 2(5657): 591-5.
50. Seidell JC, Bakx KC, Deurenberg P, van den Hoogen HJ, Hautvast JG, Stijnen T. Overweight and chronic illness--a retrospective cohort study, with a follow-up of 6-17 years, in men and women of initially 20-50 years of age. J Chronic Dis 1986; 39(8): 585-93.
51. Kaye SA, Folsom AR, Soler JT, Prineas RJ, Potter JD. Associations of body mass and fat distribution with sex hormone concentrations in postmenopausal women. Int J Epidemiol 1991; 20(1): 151-6.
52. Abramson JH, Hopp C, Epstein LM. The epidemiology of varicose veins. A survey in western Jerusalem. J Epidemiol Community Health 1981; 35(3): 213-7.
53. Benjamin MM, Khalil RA. Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease. EXS 2012; 103: 209-79.
54. Gross J, Lapiere CM. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci U S A 1962; 48: 1014-22.
55. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92(8): 827-39.
56. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90(3): 251-62.
57. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008; 75(2): 346-59.
58. Nagase H, Fushimi K. Elucidating the function of non catalytic domains of collagenases and aggrecanases. Connect Tissue Res 2008; 49(3): 169-74.
59. Chung L, Dinakarpandian D, Yoshida N, et al. Collagenase unwinds triple-helical collagen prior to peptide bond hydrolysis. EMBO J 2004; 23(15): 3020-30.
60. Dalvie D, Cosker T, Boyden T, Zhou S, Schroeder C, Potchoiba MJ. Metabolism distribution and excretion of a matrix metalloproteinase-13 inhibitor, 4-[4-(4-fluorophenoxy)-benzenesulfonylamino]tetrahydropyran-4-carboxylic acid hydroxyamide (CP-544439), in rats and dogs: assessment of the metabolic profile of CP-544439 in plasma and urine of humans. Drug Metab Dispos 2008; 36(9): 1869-83.
61. Allan JA, Docherty AJ, Barker PJ, Huskisson NS, Reynolds JJ, Murphy G. Binding of gelatinases A and B to type-I collagen and other matrix components. Biochem J 1995; 309 (Pt 1): 299-306.
62. Aimes RT, Quigley JP. Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4-and 1/4-length fragments. J Biol Chem 1995; 270(11): 5872-6.
63. Patterson ML, Atkinson SJ, Knauper V, Murphy G. Specific collagenolysis by gelatinase A, MMP-2, is determined by the hemopexin domain and not the fibronectin-like domain. FEBS Lett 2001; 503(2-3): 158-62.
64. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69(3): 562-73.
65. Pei D, Weiss SJ. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 1995; 375(6528): 244-7.
66. Uria JA, Lopez-Otin C. Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. Cancer Res 2000; 60(17): 4745-51.
67. Park HI, Ni J, Gerkema FE, Liu D, Belozerov VE, Sang QX. Identification and characterization of human endometase (Matrix metalloproteinase-26) from endometrial tumor. J Biol Chem 2000; 275(27): 20540-4.
68. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004; 4(8): 617-29.
69. Marchenko ND, Marchenko GN, Weinreb RN, et al. Beta-catenin regulates the gene of MMP-26, a novel metalloproteinase ex pressed both in carcinomas and normal epithelial cells. Int J Biochem Cell Biol 2004; 36(5): 942-56.
70. English WR, Holtz B, Vogt G, Knauper V, Murphy G. Characterization of the role of the "MT-loop": an eight-amino acid insertion specific to progelatinase A (MMP2) activating membrane-type matrix metalloproteinases. J Biol Chem 2001; 276(45): 42018-26.
71. Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 1997; 272(4): 2446-51.
72. Knauper V, Will H, Lopez-Otin C, et al. Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J Biol Chem 1996; 271(29): 17124-31.
73. Shipley JM, Wesselschmidt RL, Kobayashi DK, Ley TJ, Shapiro SD. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci U S A 1996; 93(9): 3942-6.
74. Kerkela E, Bohling T, Herva R, Uria JA, Saarialho-Kere U. Human macrophage metalloelastase (MMP-12) expression is induced in chondrocytes during fetal development and malignant transformation. Bone 2001; 29(5): 487-93.
75. Hou P, Troen T, Ovejero MC, et al. Matrix metalloproteinase-12 (MMP-12) in osteoclasts: new lesson on the involvement of MMPs in bone resorption. Bone 2004; 34(1): 37-47.
76. Stracke JO, Fosang AJ, Last K, et al. Matrix metalloproteinases 19 and 20 cleave aggrecan and cartilage oligomeric matrix protein (COMP). FEBS Lett 2000; 478(1-2): 52-6.
77. Sadowski T, Dietrich S, Muller M, et al. Matrix metalloproteinase-19 expression in normal and diseased skin: dysregulation by epidermal proliferation. J Invest Dermatol 2003; 121(5): 989-96.
78. Sadowski T, Dietrich S, Koschinsky F, Sedlacek R. Matrix metalloproteinase 19 regulates insulin-like growth factor-mediated proliferation, migration, and adhesion in human keratinocytes through proteolysis of insulin-like growth factor binding protein-3. Mol Biol Cell 2003; 14(11): 4569-80.
79. Sadowski T, Dietrich S, Koschinsky F, et al. Matrix metalloproteinase 19 processes the laminin 5 gamma 2 chain and induces epithelial cell migration. Cell Mol Life Sci 2005; 62(7-8): 870-80.
80. Pendas AM, Folgueras AR, Llano E, et al. Diet-induced obesity and reduced skin cancer susceptibility in matrix metalloproteinase 19-deficient mice. Mol Cell Biol 2004; 24(12): 5304-13.
81. Ryu OH, Fincham AG, Hu CC, et al. Characterization of recombinant pig enamelysin activity and cleavage of recombinant pig and mouse amelogenins. J Dent Res 1999; 78(3): 743-50.
82. Li W, Gibson CW, Abrams WR, Andrews DW, DenBesten PK. Reduced hydrolysis of amelogenin may result in X-linked amelogenesis imperfecta. Matrix Biol 2001; 19(8): 755-60.
83. Skoog T, Ahokas K, Orsmark C, Jeskanen L, Isaka K, Saarialho-Kere U. MMP-21 is expressed by macrophages and fibroblasts in vivo and in culture. Exp Dermatol 2006; 15(10): 775-83.
84. Ahokas K, Lohi J, Illman SA, et al. Matrix metalloproteinase-21 is expressed epithelially during development and in cancer and is upregulated by transforming growth factor-beta1 in keratinocytes. Lab Invest 2003; 83(12): 1887-99.
85. Yang M, Kurkinen M. Cloning and characterization of a novel matrix metalloproteinase (MMP), CMMP, from chicken embryo fibroblasts. CMMP, Xenopus XMMP, and human MMP19 have a conserved unique cysteine in the catalytic domain. J Biol Chem 1998; 273(28): 17893-900.
86. Pei D, Kang T, Qi H. Cysteine array matrix metalloproteinase (CAMMP)/ MMP-23 is a type II transmembrane matrix metalloproteinase regulated by a single cleavage for both secretion and activation. J Biol Chem 2000; 275(43): 33988-97.
87. Velasco G, Pendas AM, Fueyo A, Knauper V, Murphy G, Lopez-Otin C. Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members. J Biol Chem 1999; 274(8): 4570-6.
88. Cauwe B, Van den Steen PE, Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol 2007; 42(3): 113-85.
89. Bar-Or A, Nuttall RK, Duddy M, et al. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain 2003; 126(Pt 12): 2738-49.
90. Marchenko GN, Strongin AY. MMP-28, a new human matrix metalloproteinase with an unusual cysteine-switch sequence is widely expressed in tumors. Gene 2001; 265(1-2): 87-93.
91. Lohi J, Wilson CL, Roby JD, Parks WC. Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury. J Biol Chem 2001; 276(13): 10134-44.
92. Saarialho-Kere U, Kerkela E, Jahkola T, Suomela S, Keski-Oja J, Lohi J. Epilysin (MMP-28) expression is associated with cell proliferation during epithelial repair. J Invest Dermatol 2002; 119(1): 14-21.
93. Kevorkian L, Young DA, Darrah C, et al. Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis Rheum 2004; 50(1): 131-41.
94. Momohara S, Okamoto H, Komiya K, et al. Matrix metalloproteinase 28/epilysin expression in cartilage from patients with rheumatoid arthritis and osteoarthritis: comment on the article by Kevorkian et al. Arthritis Rheum 2004; 50(12): 4074-5; author reply 5.
95. Gillespie DL, Patel A, Fileta B, et al. Varicose veins possess greater quantities of MMP-1 than normal veins and demonstrate regional variation in MMP-1 and MMP-13. J Surg Res 2002; 106(2): 233-8.
96. Kowalewski R, Sobolewski K, Wolanska M, Gacko M. Matrix metalloproteinases in the vein wall. Int Angiol 2004; 23(2): 164-9.
97. Woodside KJ, Hu M, Burke A, et al. Morphologic characteristics of varicose veins: possible role of metalloproteinases. J Vasc Surg 2003; 38(1): 162-9.
98. Aravind B, Saunders B, Navin T, et al. Inhibitory effect of TIMP influences the morphology of varicose veins. Eur J Vasc Endovasc Surg 2010; 40(6): 754-65.
99. Kosugi I, Urayama H, Kasashima F, Ohtake H, Watanabe Y. Matrix metalloproteinase-9 and urokinase-type plasminogen activator in varicose veins. Ann Vasc Surg 2003; 17(3): 234-8.
100. Sayer GL, Smith PD. Immunocytochemical characterisation of the inflammatory cell infiltrate of varicose veins. Eur J Vasc Endovasc Surg 2004; 28(5): 479-83.
101. Takase S, Bergan JJ, Schmid-Schonbein G. Expression of adhesion molecules and cytokines on saphenous veins in chronic venous insufficiency. Ann Vasc Surg 2000; 14(5): 427-35.
102. Myers KA, Jolley D, Clough A, Kirwan J. Outcome of ultrasoundguided sclerotherapy for varicose veins: medium-term results assessed by ultrasound surveillance. Eur J Vasc Endovasc Surg 2007; 33(1): 116-21.
103. Ono T, Bergan JJ, Schmid-Schonbein GW, Takase S. Monocyte infiltration into venous valves. J Vasc Surg 1998; 27(1): 158-66.
104. Chu HB, Yan F, Zhao JH, Xu YB, Wang T, Guo WJ. Assessment of the Infiltration of Inflammatory Cells in the Walls of Thrombotic Varicose Veins. Angiology 2012.
105. Herouy Y, May AE, Pornschlegel G, et al. Lipodermatosclerosis is characterized by elevated expression and activation of matrix metalloproteinases: implications for venous ulcer formation. J Invest Dermatol 1998; 111(5): 822-7.
106. Mendez MV, Raffetto JD, Phillips T, Menzoian JO, Park HY. The proliferative capacity of neonatal skin fibroblasts is reduced after exposure to venous ulcer wound fluid: A potential mechanism for senescence in venous ulcers. J Vasc Surg 1999; 30(4): 734-43.
107. Raffetto JD, Mendez MV, Marien BJ, et al. Changes in cellular motility and cytoskeletal actin in fibroblasts from patients with chronic venous insufficiency and in neonatal fibroblasts in the presence of chronic wound fluid. J Vasc Surg 2001; 33(6): 1233-41.
108. Harris IR, Yee KC, Walters CE, et al. Cytokine and protease levels in healing and non-healing chronic venous leg ulcers. Exp Dermatol 1995; 4(6): 342-9.
109. Ongenae KC, Phillips TJ, Park HY. Level of fibronectin mRNA is markedly increased in human chronic wounds. Dermatol Surg 2000; 26(5): 447-51.
110. Wysocki AB, Staiano-Coico L, Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol 1993; 101(1): 64-8.
111. Weckroth M, Vaheri A, Lauharanta J, Sorsa T, Konttinen YT. Matrix metalloproteinases, gelatinase and collagenase, in chronic leg ulcers. J Invest Dermatol 1996; 106(5): 1119-24.
112. Vaalamo M, Mattila L, Johansson N, et al. Distinct populations of stromal cells express collagenase-3 (MMP-13) and collagenase-1 (MMP-1) in chronic ulcers but not in normally healing wounds. J Invest Dermatol 1997; 109(1): 96-101.
113. Herouy Y, Mellios P, Bandemir E, et al. Inflammation in stasis dermatitis upregulates MMP-1, MMP-2 and MMP-13 expression. J Dermatol Sci 2001; 25(3): 198-205.
114. Ulrich D, Lichtenegger F, Unglaub F, Smeets R, Pallua N. Effect of chronic wound exudates and MMP-2/-9 inhibitor on angiogenesis in vitro. Plast Reconstr Surg 2005; 116(2): 539-45.
115. Saito S, Trovato MJ, You R, et al. Role of matrix metalloproteinases 1, 2, and 9 and tissue inhibitor of matrix metalloproteinase-1 in chronic venous insufficiency. J Vasc Surg 2001; 34(5): 930-8.
116. Raffetto JD, Vasquez R, Goodwin DG, Menzoian JO. Mitogenactivated protein kinase pathway regulates cell proliferation in venous ulcer fibroblasts. Vasc Endovascular Surg 2006; 40(1): 59-66.
117. Seah CC, Phillips TJ, Howard CE, et al. Chronic wound fluid suppresses proliferation of dermal fibroblasts through a Ras-mediated signaling pathway. J Invest Dermatol 2005; 124(2): 466-74.
118. Hieta N, Impola U, Lopez-Otin C, Saarialho-Kere U, Kahari VM. Matrix metalloproteinase-19 expression in dermal wounds and by fibroblasts in culture. J Invest Dermatol 2003; 121(5): 997-1004.
119. Norgauer J, Hildenbrand T, Idzko M, et al. Elevated expression of extracellular matrix metalloproteinase inducer (CD147) and membrane-type matrix metalloproteinases in venous leg ulcers. Br J Dermatol 2002; 147(6): 1180-6.
120. Mwaura B, Mahendran B, Hynes N, et al. The impact of differential expression of extracellular matrix metalloproteinase inducer, matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2 and PDGF-AA on the chronicity of venous leg ulcers. Eur J Vasc Endovasc Surg 2006; 31(3): 306-10.
121. Beidler SK, Douillet CD, Berndt DF, Keagy BA, Rich PB, Marston WA. Multiplexed analysis of matrix metalloproteinases in leg ulcer tissue of patients with chronic venous insufficiency before and after compression therapy. Wound Repair Regen 2008; 16(5): 642-8.
122. Vaalamo M, Leivo T, Saarialho-Kere U. Differential expression of tissue inhibitors of metalloproteinases (TIMP-1,-2,-3, and-4) in normal and aberrant wound healing. Hum Pathol 1999; 30(7): 795-802.
123. Caggiati A, Bergan JJ, Gloviczki P, Jantet G, Wendell-Smith CP, Partsch H. Nomenclature of the veins of the lower limbs: an international interdisciplinary consensus statement. J Vasc Surg 2002; 36(2): 416-22.
124. Pollack AA, Wood EH. Venous pressure in the saphenous vein at the ankle in man during exercise and changes in posture. J Appl Physiol 1949; 1(9): 649-62.
125. Recek C. Conception of the venous hemodynamics in the lower extremity. Angiology 2006; 57(5): 556-63.
126. Jacob MP, Cazaubon M, Scemama A, et al. Plasma matrix metalloproteinase-9 as a marker of blood stasis in varicose veins. Circulation 2002; 106(5): 535-8.
127. Lim CS, Qiao X, Reslan OM, et al. Prolonged mechanical stretch is associated with upregulation of hypoxia-inducible factors and reduced contraction in rat inferior vena cava. J Vasc Surg 2011; 53(3): 764-73.
128. Pascarella L, Penn A, Schmid-Schonbein GW. Venous hypertension and the inflammatory cascade: major manifestations and trigger mechanisms. Angiology 2005; 56 Suppl 1: S3-10.
129. Takase S, Pascarella L, Bergan JJ, Schmid-Schonbein GW. Hypertension-induced venous valve remodeling. J Vasc Surg 2004; 39(6): 1329-34.
130. Pascarella L, Schmid-Schonbein GW, Bergan J. An animal model of venous hypertension: the role of inflammation in venous valve failure. J Vasc Surg 2005; 41(2): 303-11.
131. Semenza GL. Regulation of oxygen homeostasis by hypoxiainducible factor 1. Physiology (Bethesda) 2009; 24: 97-106.
132. Lim CS, Kiriakidis S, Paleolog EM, Davies AH. Increased activation of the hypoxia-inducible factor pathway in varicose veins. J Vasc Surg 2012; 55(5): 1427-39.
133. Gaber T, Dziurla R, Tripmacher R, Burmester GR, Buttgereit F. Hypoxia inducible factor (HIF) in rheumatology: low O2! See what HIF can do! Ann Rheum Dis 2005; 64(7): 971-80.
134. Kim CH, Cho YS, Chun YS, Park JW, Kim MS. Early expression of myocardial HIF-1alpha in response to mechanical stresses: regulation by stretch-activated channels and the phosphatidylinositol 3-kinase signaling pathway. Circ Res 2002; 90(2): E25-33.
135. Petersen W, Varoga D, Zantop T, Hassenpflug J, Mentlein R, Pufe T. Cyclic strain influences the expression of the vascular endothelial growth factor (VEGF) and the hypoxia inducible factor 1 alpha (HIF-1alpha) in tendon fibroblasts. J Orthop Res 2004; 22(4): 847-53.
136. Chang H, Shyu KG, Wang BW, Kuan P. Regulation of hypoxiainducible factor-1alpha by cyclical mechanical stretch in rat vascular smooth muscle cells. Clin Sci (Lond) 2003; 105(4): 447-56.
137. Milkiewicz M, Doyle JL, Fudalewski T, Ispanovic E, Aghasi M, Haas TL. HIF-1alpha and HIF-2alpha play a central role in stretchinduced but not shear-stress-induced angiogenesis in rat skeletal muscle. J Physiol 2007; 583(Pt 2): 753-66.
138. Ke Q, Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 2006; 70(5): 1469-80.
139. Fujiwara S, Nakagawa K, Harada H, et al. Silencing hypoxiainducible factor-1alpha inhibits cell migration and invasion under hypoxic environment in malignant gliomas. Int J Oncol 2007; 30(4): 793-802.
140. Misra S, Fu AA, Rajan DK, et al. Expression of hypoxia inducible factor-1 alpha, macrophage migration inhibition factor, matrix metalloproteinase-2 and-9, and their inhibitors in hemodialysis grafts and arteriovenous fistulas. J Vasc Interv Radiol 2008; 19(2 Pt 1): 252-9.
141. Haga JH, Li YS, Chien S. Molecular basis of the effects of mechanical stretch on vascular smooth muscle cells. J Biomech 2007; 40(5): 947-60.
142. Thodeti CK, Matthews B, Ravi A, et al. TRPV4 channels mediate cyclic strain-induced endothelial cell reorientation through integrinto-integrin signaling. Circ Res 2009; 104(9): 1123-30.
143. Oktay M, Wary KK, Dans M, Birge RB, Giancotti FG. Integrinmediated activation of focal adhesion kinase is required for signaling to Jun NH2-terminal kinase and progression through the G1 phase of the cell cycle. J Cell Biol 1999; 145(7): 1461-9.
144. Li C, Xu Q. Mechanical stress-initiated signal transductions in vascular smooth muscle cells. Cell Signal 2000; 12(7): 435-45.
145. Hishikawa K, Oemar BS, Yang Z, Luscher TF. Pulsatile stretch stimulates superoxide production and activates nuclear factorkappa B in human coronary smooth muscle. Circ Res 1997; 81(5): 797-803.
146. Ungvari Z, Csiszar A, Huang A, Kaminski PM, Wolin MS, Koller A. High pressure induces superoxide production in isolated arteries via protein kinase C-dependent activation of NAD(P)H oxidase. Circulation 2003; 108(10): 1253-8.
147. Bode W, Gomis-Ruth FX, Stockler W. Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the 'metzincins'. FEBS Lett 1993; 331(1-2): 134-40.
148. Van Wart HE, Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A 1990; 87(14): 5578-82.
149. Browner MF, Smith WW, Castelhano AL. Matrilysin-inhibitor complexes: common themes among metalloproteases. Biochemistry 1995; 34(20): 6602-10.
150. Kester WR, Matthews BW. Crystallographic study of the binding of dipeptide inhibitors to thermolysin: implications for the mechanism of catalysis. Biochemistry 1977; 16(11): 2506-16.
151. Manzetti S, McCulloch DR, Herington AC, van der Spoel D. Modeling of enzyme-substrate complexes for the metalloproteases MMP-3, ADAM-9 and ADAM-10. J Comput Aided Mol Des 2003; 17(9): 551-65.
152. Skiles JW, Gonnella NC, Jeng AY. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr Med Chem 2001; 8(4): 425-74.
153. Lovejoy B, Hassell AM, Luther MA, Weigl D, Jordan SR. Crystal structures of recombinant 19-kDa human fibroblast collagenase complexed to itself. Biochemistry 1994; 33(27): 8207-17.
154. Suenaga N, Mori H, Itoh Y, Seiki M. CD44 binding through the hemopexin-like domain is critical for its shedding by membranetype 1 matrix metalloproteinase. Oncogene 2005; 24(5): 859-68.
155. Suzuki K, Enghild JJ, Morodomi T, Salvesen G, Nagase H. Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin). Biochemistry 1990; 29(44): 10261-70.
156. Mulvany MJ, Baumbach GL, Aalkjaer C, et al. Vascular remodeling. Hypertension 1996; 28(3): 505-6.
157. Butler GS, Butler MJ, Atkinson SJ, et al. The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem 1998; 273(2): 871-80.
158. Wang Z, Juttermann R, Soloway PD. TIMP-2 is required for efficient activation of proMMP-2 in vivo. J Biol Chem 2000; 275(34): 26411-5.
159. Itoh Y, Takamura A, Ito N, et al. Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. EMBO J 2001; 20(17): 4782-93.
160. Kudo T, Takino T, Miyamori H, Thompson EW, Sato H. Substrate choice of membrane-type 1 matrix metalloproteinase is dictated by tissue inhibitor of metalloproteinase-2 levels. Cancer Sci 2007; 98(4): 563-8.
161. van de Ven WJ, Voorberg J, Fontijn R, et al. Furin is a subtilisinlike proprotein processing enzyme in higher eukaryotes. Mol Biol Rep 1990; 14(4): 265-75.
162. Fu X, Kassim SY, Parks WC, Heinecke JW. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 2001; 276(44): 41279-87.
163. Fu X, Kao JL, Bergt C, et al. Oxidative cross-linking of tryptophan to glycine restrains matrix metalloproteinase activity: specific structural motifs control protein oxidation. J Biol Chem 2004; 279(8): 6209-12.
164. Okamoto T, Akaike T, Nagano T, et al. Activation of human neutrophil procollagenase by nitrogen dioxide and peroxynitrite: a novel mechanism for procollagenase activation involving nitric oxide. Arch Biochem Biophys 1997; 342(2): 261-74.
165. Gu Z, Kaul M, Yan B, et al. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 2002; 297(5584): 1186-90.
166. Oh C, Dong Y, Liu H, Thompson LP. Intrauterine hypoxia upregulates proinflammatory cytokines and matrix metalloproteinases in fetal guinea pig hearts. Am J Obstet Gynecol 2008; 199(1): 78 e1-6.
167. Ogata Y, Enghild JJ, Nagase H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 1992; 267(6): 3581-4.
168. Dollery CM, Libby P. Atherosclerosis and proteinase activation. Cardiovasc Res 2006; 69(3): 625-35.
169. Liu Z, Zhou X, Shapiro SD, et al. The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell 2000; 102(5): 647-55.
170. Desrochers PE, Mookhtiar K, Van Wart HE, Hasty KA, Weiss SJ. Proteolytic inactivation of alpha 1-proteinase inhibitor and alpha 1-antichymotrypsin by oxidatively activated human neutrophil metalloproteinases. J Biol Chem 1992; 267(7): 5005-12.
171. Chen LC, Noelken ME, Nagase H. Disruption of the cysteine-75 and zinc ion coordination is not sufficient to activate the precursor of human matrix metalloproteinase 3 (stromelysin 1). Biochemistry 1993; 32(39): 10289-95.
172. Iyer RP, Patterson NL, Fields GB, Lindsey ML. The history of matrix metalloproteinases: milestones, myths, and misperceptions. Am J Physiol Heart Circ Physiol 2012; 303(8): H919-30.
173. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2(3): 161-74.
174. Ravanti L, Kahari VM. Matrix metalloproteinases in wound repair (review). Int J Mol Med 2000; 6(4): 391-407.
175. Ganz T. Defensins and host defense. Science 1999; 286(5439): 420-1.
176. Wilson CL, Ouellette AJ, Satchell DP, et al. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 1999; 286(5437): 113-7.
177. Gearing AJ, Thorpe SJ, Miller K, et al. Selective cleavage of human IgG by the matrix metalloproteinases, matrilysin and stromelysin. Immunol Lett 2002; 81(1): 41-8.
178. Ruiz S, Henschen-Edman AH, Nagase H, Tenner AJ. Digestion of C1q collagen-like domain with MMPs-1,-2,-3, and-9 further defines the sequence involved in the stimulation of neutrophil superoxide production. J Leukoc Biol 1999; 66(3): 416-22.
179. Feng X, Tonnesen MG, Peerschke EI, Ghebrehiwet B. Cooperation of C1q receptors and integrins in C1q-mediated endothelial cell adhesion and spreading. J Immunol 2002; 168(5): 2441-8.
180. Rozanov DV, Ghebrehiwet B, Postnova TI, Eichinger A, Deryugina EI, Strongin AY. The hemopexin-like C-terminal domain of membrane type 1 matrix metalloproteinase regulates proteolysis of a multifunctional protein, gC1qR. J Biol Chem 2002; 277(11): 9318-25.
181. Stefanidakis M, Koivunen E. Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression. Blood 2006; 108(5): 1441-50.
182. Eck SM, Blackburn JS, Schmucker AC, Burrage PS, Brinckerhoff CE. Matrix metalloproteinase and G protein coupled receptors: coconspirators in the pathogenesis of autoimmune disease and cancer. J Autoimmun 2009; 33(3-4): 214-21.
183. Harvey MB, Leco KJ, Arcellana-Panlilio MY, Zhang X, Edwards DR, Schultz GA. Proteinase expression in early mouse embryos is regulated by leukaemia inhibitory factor and epidermal growth factor. Development 1995; 121(4): 1005-14.
184. Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 2000; 14(17): 2123-33.
185. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007; 8(3): 221-33.
186. Bosman FT, Stamenkovic I. Functional structure and composition of the extracellular matrix. J Pathol 2003; 200(4): 423-8.
187. Teti A. Regulation of cellular functions by extracellular matrix. J Am Soc Nephrol 1992; 2(10 Suppl): S83-7.
188. Jacob MP. Extracellular matrix remodeling and matrix metalloproteinases in the vascular wall during aging and in pathological conditions. Biomed Pharmacother 2003; 57(5-6): 195-202.
189. Midwood KS, Mao Y, Hsia HC, Valenick LV, Schwarzbauer JE. Modulation of cell-fibronectin matrix interactions during tissue repair. J Investig Dermatol Symp Proc 2006; 11(1): 73-8.
190. Geutjes PJ, Daamen WF, Buma P, Feitz WF, Faraj KA, van Kuppevelt TH. From molecules to matrix: construction and evaluation of molecularly defined bioscaffolds. Adv Exp Med Biol 2006; 585: 279-95.
191. Lovejoy B, Welch AR, Carr S, et al. Crystal structures of MMP-1 and-13 reveal the structural basis for selectivity of collagenase inhibitors. Nat Struct Biol 1999; 6(3): 217-21.
192. Olson MW, Toth M, Gervasi DC, Sado Y, Ninomiya Y, Fridman R. High affinity binding of latent matrix metalloproteinase-9 to the alpha2(IV) chain of collagen IV. J Biol Chem 1998; 273(17): 10672-81.
193. Porter KE, Thompson MM, Loftus IM, et al. Production and inhibition of the gelatinolytic matrix metalloproteinases in a human model of vein graft stenosis. Eur J Vasc Endovasc Surg 1999; 17(5): 404-12.
194. Mavromatis K, Fukai T, Tate M, Chesler N, Ku DN, Galis ZS. Early effects of arterial hemodynamic conditions on human saphenous veins perfused ex vivo. Arterioscler Thromb Vasc Biol 2000; 20(8): 1889-95.
195. Anstadt MP, Franga DL, Portik-Dobos V, et al. Native matrix metalloproteinase characteristics may influence early stenosis of venous versus arterial coronary artery bypass grafting conduits. Chest 2004; 125(5): 1853-8.
196. Nagakawa Y, Aoki T, Kasuya K, Tsuchida A, Koyanagi Y. Histologic features of venous invasion, expression of vascular endothelial growth factor and matrix metalloproteinase-2 and matrix metalloproteinase-9, and the relation with liver metastasis in pancreatic cancer. Pancreas 2002; 24(2): 169-78.
197. Sansilvestri-Morel P, Rupin A, Jaisson S, Fabiani JN, Verbeuren TJ, Vanhoutte PM. Synthesis of collagen is dysregulated in cultured fibroblasts derived from skin of subjects with varicose veins as it is in venous smooth muscle cells. Circulation 2002; 106(4): 479-83.
198. Gandhi RH, Irizarry E, Nackman GB, Halpern VJ, Mulcare RJ, Tilson MD. Analysis of the connective tissue matrix and proteolytic activity of primary varicose veins. J Vasc Surg 1993; 18(5): 814-20.
199. Venturi M, Bonavina L, Annoni F, et al. Biochemical assay of collagen and elastin in the normal and varicose vein wall. J Surg Res 1996; 60(1): 245-8.
200. Haviarova Z, Weismann P, Stvrtinova V, Benuska J. The determination of the collagen and elastin amount in the human varicose vein by the computer morphometric method. Gen Physiol Biophys 1999; 18 Suppl 1: 30-3.
201. Kockx MM, Knaapen MW, Bortier HE, Cromheeke KM, Boutherin-Falson O, Finet M. Vascular remodeling in varicose veins. Angiology 1998; 49(11): 871-7.
202. Kirsch D, Dienes HP, Kuchle R, et al. Changes in the extracellular matrix of the vein wall--the cause of primary varicosis? Vasa 2000; 29(3): 173-7.
203. Sansilvestri-Morel P, Fioretti F, Rupin A, et al. Comparison of extracellular matrix in skin and saphenous veins from patients with varicose veins: does the skin reflect venous matrix changes? Clin Sci (Lond) 2007; 112(4): 229-39.
204. Parra JR, Cambria RA, Hower CD, et al. Tissue inhibitor of metalloproteinase-1 is increased in the saphenofemoral junction of patients with varices in the leg. J Vasc Surg 1998; 28(4): 669-75.
205. Badier-Commander C, Verbeuren T, Lebard C, Michel JB, Jacob MP. Increased TIMP/MMP ratio in varicose veins: a possible explanation for extracellular matrix accumulation. J Pathol 2000; 192(1): 105-12.
206. Sansilvestri-Morel P, Nonotte I, Fournet-Bourguignon MP, et al. Abnormal deposition of extracellular matrix proteins by cultured smooth muscle cells from human varicose veins. J Vasc Res 1998; 35(2): 115-23.
207. Sansilvestri-Morel P, Rupin A, Jullien ND, et al. Decreased production of collagen Type III in cultured smooth muscle cells from varicose vein patients is due to a degradation by MMPs: possible implication of MMP-3. J Vasc Res 2005; 42(5): 388-98.
208. Xiao Y, Huang Z, Yin H, Zhang H, Wang S. Desmuslin gene knockdown causes altered expression of phenotype markers and differentiation of saphenous vein smooth muscle cells. J Vasc Surg 2010; 52(3): 684-90.
209. Nagareddy PR, Chow FL, Hao L, et al. Maintenance of adrenergic vascular tone by MMP transactivation of the EGFR requires PI3K and mitochondrial ATP synthesis. Cardiovasc Res 2009; 84(3): 368-77.
210. Chew DK, Conte MS, Khalil RA. Matrix metalloproteinasespecific inhibition of Ca2+ entry mechanisms of vascular contraction. J Vasc Surg 2004; 40(5): 1001-10.
211. Herouy Y, Nockowski P, Schopf E, Norgauer J. Lipodermatosclerosis and the significance of proteolytic remodeling in the pathogenesis of venous ulceration (Review). Int J Mol Med 1999; 3(5): 511-5.
212. Thulesius O. The venous wall and valvular function in chronic venous insufficiency. Int Angiol 1996; 15(2): 114-8.
213. Waitkus-Edwards KR, Martinez-Lemus LA, Wu X, et al. alpha(4)beta(1) Integrin activation of L-type calcium channels in vascular smooth muscle causes arteriole vasoconstriction. Circ Res 2002; 90(4): 473-80.
214. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. Proteinase-activated receptors. Pharmacol Rev 2001; 53(2): 245-82.
215. Hamilton JR, Nguyen PB, Cocks TM. Atypical protease-activated receptor mediates endothelium-dependent relaxation of human coronary arteries. Circ Res 1998; 82(12): 1306-11.
216. Shi ZD, Ji XY, Berardi DE, Qazi H, Tarbell JM. Interstitial flow induces MMP-1 expression and vascular SMC migration in collagen I gels via an ERK1/2-dependent and c-Jun-mediated mechanism. Am J Physiol Heart Circ Physiol 2010; 298(1): H127-35.
217. Vigetti D, Moretto P, Viola M, et al. Aortic smooth muscle cells migration and the role of metalloproteinases and hyaluronan. Connect Tissue Res 2008; 49(3): 189-92.
218. Haque NS, Fallon JT, Pan JJ, Taubman MB, Harpel PC. Chemokine receptor-8 (CCR8) mediates human vascular smooth muscle cell chemotaxis and metalloproteinase-2 secretion. Blood 2004; 103(4): 1296-304.
219. Cheng XW, Kuzuya M, Sasaki T, et al. Increased expression of elastolytic cysteine proteases, cathepsins S and K, in the neointima of balloon-injured rat carotid arteries. Am J Pathol 2004; 164(1): 243-51.
220. Johnson C, Galis ZS. Matrix metalloproteinase-2 and-9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler Thromb Vasc Biol 2004; 24(1): 54-60.
221. Jin UH, Suh SJ, Chang HW, et al. Tanshinone IIA from Salvia miltiorrhiza BUNGE inhibits human aortic smooth muscle cell migration and MMP-9 activity through AKT signaling pathway. J Cell Biochem 2008; 104(1): 15-26.
222. Yu YM, Lin HC. Curcumin prevents human aortic smooth muscle cells migration by inhibiting of MMP-9 expression. Nutr Metab Cardiovasc Dis 2010; 20(2): 125-32.
223. Cho A, Reidy MA. Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ Res 2002; 91(9): 845-51.
224. Galis ZS, Johnson C, Godin D, et al. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res 2002; 91(9): 852-9.
225. Aguilera CM, George SJ, Johnson JL, Newby AC. Relationship between type IV collagen degradation, metalloproteinase activity and smooth muscle cell migration and proliferation in cultured human saphenous vein. Cardiovasc Res 2003; 58(3): 679-88.
226. Carragher NO, Frame MC. Focal adhesion and actin dynamics: a place where kinases and proteases meet to promote invasion. Trends Cell Biol 2004; 14(5): 241-9.
227. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004; 303(5663): 1483-7.
228. Savani RC, Wang C, Yang B, et al. Migration of bovine aortic smooth muscle cells after wounding injury. The role of hyaluronan and RHAMM. J Clin Invest 1995; 95(3): 1158-68.
229. Uglow EB, Slater S, Sala-Newby GB, et al. Dismantling of cadherin-mediated cell-cell contacts modulates smooth muscle cell proliferation. Circ Res 2003; 92(12): 1314-21.
230. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005; 120(3): 303-13.
231. Somers P, Knaapen M. The histopathology of varicose vein disease. Angiology 2006; 57(5): 546-55.
232. Wali MA, Eid RA. Smooth muscle changes in varicose veins: an ultrastructural study. J Smooth Muscle Res 2001; 37(5-6): 123-35.
233. Wali MA, Eid RA. Intimal changes in varicose veins: an ultrastructural study. J Smooth Muscle Res 2002; 38(3): 63-74.
234. Elsharawy MA, Naim MM, Abdelmaguid EM, Al-Mulhim AA. Role of saphenous vein wall in the pathogenesis of primary varicose veins. Interact Cardiovasc Thorac Surg 2007; 6(2): 219-24.
235. Forough R, Koyama N, Hasenstab D, et al. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circ Res 1996; 79(4): 812-20.
236. Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of tissue inhibitor of metalloproteinase-1,-2, or-3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest 1998; 101(6): 1478-87.
237. George SJ, Lloyd CT, Angelini GD, Newby AC, Baker AH. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation 2000; 101(3): 296-304.
238. Kenagy RD, Vergel S, Mattsson E, Bendeck M, Reidy MA, Clowes AW. The role of plasminogen, plasminogen activators, and matrix metalloproteinases in primate arterial smooth muscle cell migration. Arterioscler Thromb Vasc Biol 1996; 16(11): 1373-82.
239. Islam MM, Franco CD, Courtman DW, Bendeck MP. A nonantibiotic chemically modified tetracycline (CMT-3) inhibits intimal thickening. Am J Pathol 2003; 163(4): 1557-66.
240. Lee YJ, Kim JS, Kang DG, Lee HS. Buddleja officinalis suppresses high glucose-induced vascular smooth muscle cell proliferation: role of mitogen-activated protein kinases, nuclear factor-kappaB and matrix metalloproteinases. Exp Biol Med (Maywood) 2010; 235(2): 247-55.
241. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005; 85(1): 1-31.
242. Xiao Y, Huang Z, Yin H, Lin Y, Wang S. In vitro differences between smooth muscle cells derived from varicose veins and normal veins. J Vasc Surg 2009; 50(5): 1149-54.
243. Walker HA, Whitelock JM, Garl PJ, Nemenoff RA, Stenmark KR, Weiser-Evans MC. Perlecan up-regulation of FRNK suppresses smooth muscle cell proliferation via inhibition of FAK signaling. Mol Biol Cell 2003; 14(5): 1941-52.
244. Morla AO, Mogford JE. Control of smooth muscle cell proliferation and phenotype by integrin signaling through focal adhesion kinase. Biochem Biophys Res Commun 2000; 272(1): 298-302.
245. Lucchesi PA, Sabri A, Belmadani S, Matrougui K. Involvement of metalloproteinases 2/9 in epidermal growth factor receptor transactivation in pressure-induced myogenic tone in mouse mesenteric resistance arteries. Circulation 2004; 110(23): 3587-93.
246. Hollenbeck ST, Sakakibara K, Faries PL, Workhu B, Liu B, Kent KC. Stem cell factor and c-kit are expressed by and may affect vascular SMCs through an autocrine pathway. J Surg Res 2004; 120(2): 288-94.
247. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci 2003; 116(Pt 2): 217-24.
248. Suzuki M, Raab G, Moses MA, Fernandez CA, Klagsbrun M. Matrix metalloproteinase-3 releases active heparin-binding EGFlike growth factor by cleavage at a specific juxtamembrane site. J Biol Chem 1997; 272(50): 31730-7.
249. Imai K, Hiramatsu A, Fukushima D, Pierschbacher MD, Okada Y. Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. Biochem J 1997; 322 (Pt 3): 809-14.
250. Manes S, Mira E, Barbacid MM, et al. Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J Biol Chem 1997; 272(41): 25706-12.
251. Noe V, Fingleton B, Jacobs K, et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 2001; 114(Pt 1): 111-8.
252. Steinhusen U, Weiske J, Badock V, Tauber R, Bommert K, Huber O. Cleavage and shedding of E-cadherin after induction of apoptosis. J Biol Chem 2001; 276(7): 4972-80.
253. Asamoto M, Hokaiwado N, Cho YM, et al. Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent. Cancer Res 2001; 61(12): 4693-700.
254. Fujiwara K, Matsukawa A, Ohkawara S, Takagi K, Yoshinaga M. Functional distinction between CXC chemokines, interleukin-8 (IL-8), and growth related oncogene (GRO)alpha in neutrophil infiltration. Lab Invest 2002; 82(1): 15-23.
255. McQuibban GA, Butler GS, Gong JH, et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 2001; 276(47): 43503-8.
256. Levi E, Fridman R, Miao HQ, Ma YS, Yayon A, Vlodavsky I. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci U S A 1996; 93(14): 7069-74.
257. Bendeck MP, Irvin C, Reidy MA. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res 1996; 78(1): 38-43.
258. Zempo N, Koyama N, Kenagy RD, Lea HJ, Clowes AW. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb Vasc Biol 1996; 16(1): 28-33.
259. Lovdahl C, Thyberg J, Hultgardh-Nilsson A. The synthetic metalloproteinase inhibitor batimastat suppresses injury-induced phosphorylation of MAP kinase ERK1/ERK2 and phenotypic modification of arterial smooth muscle cells in vitro. J Vasc Res 2000; 37(5): 345-54.
260. Slater SC, Koutsouki E, Jackson CL, et al. R-cadherin:beta-catenin complex and its association with vascular smooth muscle cell proliferation. Arterioscler Thromb Vasc Biol 2004; 24(7): 1204-10.
261. Bendeck MP, Conte M, Zhang M, Nili N, Strauss BH, Farwell SM. Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. Am J Pathol 2002; 160(3): 1089-95.
262. Wung BS, Cheng JJ, Hsieh HJ, Shyy YJ, Wang DL. Cyclic straininduced monocyte chemotactic protein-1 gene expression in endothelial cells involves reactive oxygen species activation of activator protein 1. Circ Res 1997; 81(1): 1-7.
263. Wu X, Shen H, Yu L, Peng M, Lai WS, Ding YL. Corticotropinreleasing hormone activates connexin 43 via activator protein-1 transcription factor in human myometrial smooth muscle cells. Am J Physiol Endocrinol Metab 2007; 293(6): E1789-94.
264. Buchwald AB, Wagner AH, Webel C, Hecker M. Decoy oligodeoxynucleotide against activator protein-1 reduces neointimal proliferation after coronary angioplasty in hypercholesterolemic minipigs. J Am Coll Cardiol 2002; 39(4): 732-8.
265. Mann MJ, Dzau VJ. Therapeutic applications of transcription factor decoy oligonucleotides. J Clin Invest 2000; 106(9): 1071-5.
266. Demicheva E, Hecker M, Korff T. Stretch-induced activation of the transcription factor activator protein-1 controls monocyte chemoattractant protein-1 expression during arteriogenesis. Circ Res 2008; 103(5): 477-84.
267. Bergman MR, Cheng S, Honbo N, Piacentini L, Karliner JS, Lovett DH. A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers. Biochem J 2003; 369(Pt 3): 485-96.
268. Feldner A, Otto H, Rewerk S, Hecker M, Korff T. Experimental hypertension triggers varicosis-like maladaptive venous remodeling through activator protein-1. FASEB J 2011; 25(10): 3613-21.
269. Geng YJ, Libby P. Progression of atheroma: a struggle between death and procreation. Arterioscler Thromb Vasc Biol 2002; 22(9): 1370-80.
270. Stoneman VE, Bennett MR. Role of apoptosis in atherosclerosis and its therapeutic implications. Clin Sci (Lond) 2004; 107(4): 343-54.
271. Hao L, Du M, Lopez-Campistrous A, Fernandez-Patron C. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ Res 2004; 94(1): 68-76.
272. Akiba S, Kumazawa S, Yamaguchi H, et al. Acceleration of matrix metalloproteinase-1 production and activation of platelet-derived growth factor receptor beta in human coronary smooth muscle cells by oxidized LDL and 4-hydroxynonenal. Biochim Biophys Acta 2006; 1763(8): 797-804.
273. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol 2001; 13(5): 555-62.
274. Almeida EA, Ilic D, Han Q, et al. Matrix survival signaling: from fibronectin via focal adhesion kinase to c-Jun NH(2)-terminal kinase. J Cell Biol 2000; 149(3): 741-54.
275. Ilic D, Almeida EA, Schlaepfer DD, Dazin P, Aizawa S, Damsky CH. Extracellular matrix survival signals transduced by focal adhesion kinase suppress p53-mediated apoptosis. J Cell Biol 1998; 143(2): 547-60.
276. Levkau B, Kenagy RD, Karsan A, et al. Activation of metalloproteinases and their association with integrins: an auxiliary apoptotic pathway in human endothelial cells. Cell Death Differ 2002; 9(12): 1360-7.
277. Somerville RP, Oblander SA, Apte SS. Matrix metalloproteinases: old dogs with new tricks. Genome Biol 2003; 4(6): 216.
278. Mannello F, Luchetti F, Falcieri E, Papa S. Multiple roles of matrix metalloproteinases during apoptosis. Apoptosis 2005; 10(1): 19-24.
279. Bond M, Murphy G, Bennett MR, et al. Localization of the death domain of tissue inhibitor of metalloproteinase-3 to the N terminus. Metalloproteinase inhibition is associated with proapoptotic activity. J Biol Chem 2000; 275(52): 41358-63.
280. Kwan JA, Schulze CJ, Wang W, et al. Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. FASEB J 2004; 18(6): 690-2.
281. Guo YH, Gao W, Li Q, Li PF, Yao PY, Chen K. Tissue inhibitor of metalloproteinases-4 suppresses vascular smooth muscle cell migration and induces cell apoptosis. Life Sci 2004; 75(20): 2483-93.
282. Feletou M, Vanhoutte PM. Endothelium-derived hyperpolarizing factor: where are we now? Arterioscler Thromb Vasc Biol 2006; 26(6): 1215-25.
283. Cai WJ, Kocsis E, Luo X, Schaper W, Schaper J. Expression of endothelial nitric oxide synthase in the vascular wall during arteriogenesis. Mol Cell Biochem 2004; 264(1-2): 193-200.
284. Coleman HA, Tare M, Parkington HC. Endothelial potassium channels, endothelium-dependent hyperpolarization and the regulation of vascular tone in health and disease. Clin Exp Pharmacol Physiol 2004; 31(9): 641-9.
285. Coleman HA, Tare M, Parkington HC. K+ currents underlying the action of endothelium-derived hyperpolarizing factor in guinea-pig, rat and human blood vessels. J Physiol 2001; 531(Pt 2): 359-73.
286. Cena J, Lalu MM, Rosenfelt C, Schulz R. Endothelial dependence of matrix metalloproteinase-mediated vascular hyporeactivity caused by lipopolysaccharide. Eur J Pharmacol 2008; 582(1-3): 116-22.
287. Cohen RA. The endothelium-derived hyperpolarizing factor puzzle: a mechanism without a mediator? Circulation 2005; 111(6): 724-7.
288. Lee HY, You HJ, Won JY, et al. Forkhead factor, FOXO3a, induces apoptosis of endothelial cells through activation of matrix metalloproteinases. Arterioscler Thromb Vasc Biol 2008; 28(2): 302-8.
289. Jacob-Ferreira AL, Palei AC, Cau SB, et al. Evidence for the involvement of matrix metalloproteinases in the cardiovascular effects produced by nicotine. Eur J Pharmacol 2010; 627(1-3): 216-22.
290. Castro MM, Rizzi E, Rodrigues GJ, et al. Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. Free Radic Biol Med 2009; 46(9): 1298-307.
291. Goerge T, Barg A, Schnaeker EM, et al. Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. Cancer Res 2006; 66(15): 7766-74.
292. Tarin C, Gomez M, Calvo E, Lopez JA, Zaragoza C. Endothelial nitric oxide deficiency reduces MMP-13-mediated cleavage of ICAM-1 in vascular endothelium: a role in atherosclerosis. Arterioscler Thromb Vasc Biol 2009; 29(1): 27-32.
293. Aunapuu M, Arend A. Histopathological changes and expression of adhesion molecules and laminin in varicose veins. Vasa 2005; 34(3): 170-5.
294. Louboutin JP, Agrawal L, Reyes BA, Van Bockstaele EJ, Strayer DS. HIV-1 gp120-induced injury to the blood-brain barrier: role of metalloproteinases 2 and 9 and relationship to oxidative stress. J Neuropathol Exp Neurol 2010; 69(8): 801-16.
295. Thanabalasundaram G, Pieper C, Lischper M, Galla HJ. Regulation of the blood-brain barrier integrity by pericytes via matrix metalloproteinases mediated activation of vascular endothelial growth factor in vitro. Brain Res 2010; 1347: 1-10.
296. Lischper M, Beuck S, Thanabalasundaram G, Pieper C, Galla HJ. Metalloproteinase mediated occludin cleavage in the cerebral microcapillary endothelium under pathological conditions. Brain Res 2010; 1326: 114-27.
297. Horner J, Fernandes J, Fernandes E, Nicolaides AN. Value of graduated compression stockings in deep venous insufficiency. Br Med J 1980; 280(6217): 820-1.
298. Wells PS, Lensing AW, Hirsh J. Graduated compression stockings in the prevention of postoperative venous thromboembolism. A meta-analysis. Arch Intern Med 1994; 154(1): 67-72.
299. Motykie GD, Caprini JA, Arcelus JI, Reyna JJ, Overom E, Mokhtee D. Evaluation of therapeutic compression stockings in the treatment of chronic venous insufficiency. Dermatol Surg 1999; 25(2): 116-20.
300. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 Suppl): 338S-400S.
301. Amaragiri SV, Lees TA. Elastic compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev 2000; (3): CD001484.
302. Mayberry JC, Moneta GL, DeFrang RD, Porter JM. The influence of elastic compression stockings on deep venous hemodynamics. J Vasc Surg 1991; 13(1): 91-9; discussion 9-100.
303. Ibegbuna V, Delis KT, Nicolaides AN, Aina O. Effect of elastic compression stockings on venous hemodynamics during walking. J Vasc Surg 2003; 37(2): 420-5.
304. Bergan JJ. Chronic venous insufficiency and the therapeutic effects of Daflon 500 mg. Angiology 2005; 56 Suppl 1: S21-4.
305. Boisseau MR. Pharmacological targets of drugs employed in chronic venous and lymphatic insufficiency. Int Angiol 2002; 21(2 Suppl 1): 33-9.
306. Carrasco OF, Vidrio H. Endothelium protectant and contractile effects of the antivaricose principle escin in rat aorta. Vascul Pharmacol 2007; 47(1): 68-73.
307. Raffetto JD, Khalil RA. Ca(2+)-dependent contraction by the saponoside escin in rat vena cava: implications in venotonic treatment of varicose veins. J Vasc Surg 2011; 54(2): 489-96.
308. Le Devehat C, Khodabandehlou T, Vimeux M, Kempf C. Evaluation of haemorheological and microcirculatory disturbances in chronic venous insufficiency: activity of Daflon 500 mg. Int J Microcirc Clin Exp 1997; 17 Suppl 1: 27-33.
309. Cesarone MR, Belcaro G, Pellegrini L, et al. Venoruton vs Daflon: evaluation of effects on quality of life in chronic venous insufficiency. Angiology 2006; 57(2): 131-8.
310. Cesarone MR, Belcaro G, Pellegrini L, et al. Circulating endothelial cells in venous blood as a marker of endothelial damage in chronic venous insufficiency: improvement with venoruton. J Cardiovasc Pharmacol Ther 2006; 11(1): 93-8.
311. Janssens D, Michiels C, Guillaume G, Cuisinier B, Louagie Y, Remacle J. Increase in circulating endothelial cells in patients with primary chronic venous insufficiency: protective effect of Ginkor Fort in a randomized double-blind, placebo-controlled clinical trial. J Cardiovasc Pharmacol 1999; 33(1): 7-11.
312. Geroulakos G, Nicolaides AN. Controlled studies of Daflon 500 mg in chronic venous insufficiency. Angiology 1994; 45(6 Pt 2): 549-53.
313. Vanscheidt W, Rabe E, Naser-Hijazi B, et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebocontrolled randomised study. Vasa 2002; 31(3): 185-90.
314. Roztocil K, Stvrtinova V, Strejcek J. Efficacy of a 6-month treatment with Daflon 500 mg in patients with venous leg ulcers associated with chronic venous insufficiency. Int Angiol 2003; 22(1): 24-31.
315. Siebert U, Brach M, Sroczynski G, Berla K. Efficacy, routine effectiveness, and safety of horsechestnut seed extract in the treatment of chronic venous insufficiency. A meta-analysis of randomized controlled trials and large observational studies. Int Angiol 2002; 21(4): 305-15.
316. Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database Syst Rev 2006; (1): CD003230.
317. Falanga V, Fujitani RM, Diaz C, et al. Systemic treatment of venous leg ulcers with high doses of pentoxifylline: efficacy in a randomized, placebo-controlled trial. Wound Repair Regen 1999; 7(4): 208-13.
318. Belcaro G, Cesarone MR, Nicolaides AN, De Sanctis MT, Incandela L, Geroulakos G. Treatment of venous ulcers with pentoxifylline: a 6-month randomized, double-blind, placebo controlled trial. Angiology 2002; 53 Suppl 1: S45-7.
319. Kalus U, Koscielny J, Grigorov A, Schaefer E, Peil H, Kiesewetter H. Improvement of cutaneous microcirculation and oxygen supply in patients with chronic venous insufficiency by orally administered extract of red vine leaves AS 195: a randomised, doubleblind, placebo-controlled, crossover study. Drugs R D 2004; 5(2): 63-71.
320. Milio G, Mina C, Cospite V, Almasio PL, Novo S. Efficacy of the treatment with prostaglandin E-1 in venous ulcers of the lower limbs. J Vasc Surg 2005; 42(2): 304-8.
321. Kahle B, Leng K. Efficacy of sclerotherapy in varicose veins--prospective, blinded, placebo-controlled study. Dermatol Surg 2004; 30(5): 723-8; discussion 8.
322. Breu FX, Guggenbichler S. European Consensus Meeting on Foam Sclerotherapy, April, 4-6, 2003, Tegernsee, Germany. Dermatol Surg 2004; 30(5): 709-17; discussion 17.
323. Frullini A, Cavezzi A. Sclerosing foam in the treatment of varicose veins and telangiectases: history and analysis of safety and complications. Dermatol Surg 2002; 28(1): 11-5.
324. Wollmann JC. The history of sclerosing foams. Dermatol Surg 2004; 30(5): 694-703; discussion
325. Proebstle TM, Lehr HA, Kargl A, et al. Endovenous treatment of the greater saphenous vein with a 940-nm diode laser: thrombotic occlusion after endoluminal thermal damage by laser-generated steam bubbles. J Vasc Surg 2002; 35(4): 729-36.
326. Agus GB, Mancini S, Magi G. The first 1000 cases of Italian Endovenous-laser Working Group (IEWG). Rationale, and long-term outcomes for the 1999-2003 period. Int Angiol 2006; 25(2): 209-15.
327. Min RJ, Khilnani N, Zimmet SE. Endovenous laser treatment of saphenous vein reflux: long-term results. J Vasc Interv Radiol 2003; 14(8): 991-6.
328. Merchant RF, Pichot O, Myers KA. Four-year follow-up on endovascular radiofrequency obliteration of great saphenous reflux. Dermatol Surg 2005; 31(2): 129-34.
329. Sarin S, Scurr JH, Coleridge Smith PD. Stripping of the long saphenous vein in the treatment of primary varicose veins. Br J Surg 1994; 81(10): 1455-8.
330. Aremu MA, Mahendran B, Butcher W, et al. Prospective randomized controlled trial: conventional versus powered phlebectomy. J Vasc Surg 2004; 39(1): 88-94.
331. Barwell JR, Davies CE, Deacon J, et al. Comparison of surgery and compression with compression alone in chronic venous ulceration (ESCHAR study): randomised controlled trial. Lancet 2004; 363(9424): 1854-9.
332. Kontogiorgis CA, Papaioannou P, Hadjipavlou-Litina DJ. Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results. Curr Med Chem 2005; 12(3): 339-55.
333. Hu J, Van den Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007; 6(6): 480-98.
334. Murphy G, Houbrechts A, Cockett MI, Williamson RA, O'Shea M, Docherty AJ. The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry 1991; 30(33): 8097-102.
335. Williamson RA, Marston FA, Angal S, et al. Disulphide bond assignment in human tissue inhibitor of metalloproteinases (TIMP). Biochem J 1990; 268(2): 267-74.
336. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002; 115(Pt 19): 3719-27.
337. Will H, Atkinson SJ, Butler GS, Smith B, Murphy G. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. J Biol Chem 1996; 271(29): 17119-23.
338. Amour A, Knight CG, Webster A, et al. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett 2000; 473(3): 275-9.
339. Jacobsen J, Visse R, Sorensen HP, et al. Catalytic properties of ADAM12 and its domain deletion mutants. Biochemistry 2008; 47(2): 537-47.
340. Kashiwagi M, Tortorella M, Nagase H, Brew K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem 2001; 276(16): 12501-4.
341. Rodriguez-Manzaneque JC, Westling J, Thai SN, et al. ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. Biochem Biophys Res Commun 2002; 293(1): 501-8.
342. Leco KJ, Waterhouse P, Sanchez OH, et al. Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). J Clin Invest 2001; 108(6): 817-29.
343. Fata JE, Leco KJ, Voura EB, et al. Accelerated apoptosis in the Timp-3-deficient mammary gland. J Clin Invest 2001; 108(6): 831-41.
344. Batra J, Robinson J, Soares AS, Fields AP, Radisky DC, Radisky ES. Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: binding studies and crystal structure. J Biol Chem 2012; 287(19): 15935-46.
345. Meng Q, Malinovskii V, Huang W, et al. Residue 2 of TIMP-1 is a major determinant of affinity and specificity for matrix metalloproteinases but effects of substitutions do not correlate with those of the corresponding P1' residue of substrate. J Biol Chem 1999; 274(15): 10184-9.
346. Iyer S, Wei S, Brew K, Acharya KR. Crystal structure of the catalytic domain of matrix metalloproteinase-1 in complex with the inhibitory domain of tissue inhibitor of metalloproteinase-1. J Biol Chem 2007; 282(1): 364-71.
347. Vallon R, Muller R, Moosmayer D, Gerlach E, Angel P. The catalytic domain of activated collagenase I (MMP-1) is absolutely required for interaction with its specific inhibitor, tissue inhibitor of metalloproteinases-1 (TIMP-1). Eur J Biochem 1997; 244(1): 81-8.
348. Strickland DK, Ashcom JD, Williams S, Burgess WH, Migliorini M, Argraves WS. Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. J Biol Chem 1990; 265(29): 17401-4.
349. Higashi S, Miyazaki K. Novel processing of beta-amyloid precursor protein catalyzed by membrane type 1 matrix metalloproteinase releases a fragment lacking the inhibitor domain against gelatinase A. Biochemistry 2003; 42(21): 6514-26.
350. Mott JD, Thomas CL, Rosenbach MT, Takahara K, Greenspan DS, Banda MJ. Post-translational proteolytic processing of procollagen C-terminal proteinase enhancer releases a metalloproteinase inhibitor. J Biol Chem 2000; 275(2): 1384-90.
351. Herman MP, Sukhova GK, Kisiel W, et al. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest 2001; 107(9): 1117-26.
352. Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med 2008; 29(5): 290-308.
353. Rao BG. Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies. Curr Pharm Des 2005; 11(3): 295-322.
354. Jacobsen JA, Major Jourden JL, Miller MT, Cohen SM. To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition. Biochim Biophys Acta 2010; 1803(1): 72-94.
355. Brown S, Meroueh SO, Fridman R, Mobashery S. Quest for selectivity in inhibition of matrix metalloproteinases. Curr Top Med Chem 2004; 4(12): 1227-38.
356. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997; 15(1): 61-75.
357. Cherney RJ, Mo R, Meyer DT, et al. Sultam hydroxamates as novel matrix metalloproteinase inhibitors. J Med Chem 2004; 47(12): 2981-3.
358. Nakatani S, Ikura M, Yamamoto S, et al. Design and synthesis of novel metalloproteinase inhibitors. Bioorg Med Chem 2006; 14(15): 5402-22.
359. Rossello A, Nuti E, Catalani MP, et al. A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs. Bioorg Med Chem Lett 2005; 15(9): 2311-4.
360. Subramaniam R, Haldar MK, Tobwala S, Ganguly B, Srivastava DK, Mallik S. Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors. Bioorg Med Chem Lett 2008; 18(11): 3333-7.
361. Whitlock GA, Dack KN, Dickinson RP, Lewis ML. A novel series of highly selective inhibitors of MMP-3. Bioorg Med Chem Lett 2007; 17(24): 6750-3.
362. Vihinen P, Ala-aho R, Kahari VM. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 2005; 5(3): 203-20.
363. Fingleton B. MMPs as therapeutic targets--still a viable option? Semin Cell Dev Biol 2008; 19(1): 61-8.
364. Jani M, Tordai H, Trexler M, Banyai L, Patthy L. Hydroxamatebased peptide inhibitors of matrix metalloprotease 2. Biochimie 2005; 87(3-4): 385-92.
365. Trexler M, Briknarova K, Gehrmann M, Llinas M, Patthy L. Peptide ligands for the fibronectin type II modules of matrix metalloproteinase 2 (MMP-2). J Biol Chem 2003; 278(14): 12241-6.
366. Scozzafava A, Supuran CT. Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. J Med Chem 2000; 43(20): 3677-87.
367. Levin JI, Chen JM, Cheung K, et al. Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates. Bioorg Med Chem Lett 2003; 13(16): 2799-803.
368. Cherney RJ, King BW, Gilmore JL, et al. Conversion of potent MMP inhibitors into selective TACE inhibitors. Bioorg Med Chem Lett 2006; 16(4): 1028-31.
369. Pochetti G, Gavuzzo E, Campestre C, et al. Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. J Med Chem 2006; 49(3): 923-31.
370. Ma D, Wu W, Yang G, Li J, Ye Q. Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors. Bioorg Med Chem Lett 2004; 14(1): 47-50.
371. Pikul S, McDow Dunham KL, Almstead NG, et al. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases. J Med Chem 1999; 42(1): 87-94.
372. Fujisawa T, Katakura S, Odake S, et al. Design and synthesis of carboxylate inhibitors for matrix metalloproteinases. Chem Pharm Bull (Tokyo) 2001; 49(10): 1272-9.
373. Matter H, Schudok M, Schwab W, et al. Tetrahydroisoquinoline-3-carboxylate based matrix-metalloproteinase inhibitors: design, synthesis and structure-activity relationship. Bioorg Med Chem 2002; 10(11): 3529-44.
374. Janusz MJ, Hookfin EB, Brown KK, et al. Comparison of the pharmacology of hydroxamate-and carboxylate-based matrix metalloproteinase inhibitors (MMPIs) for the treatment of osteoarthritis. Inflamm Res 2006; 55(2): 60-5.
375. Ilies M, Banciu MD, Scozzafava A, Ilies MA, Caproiu MT, Supuran CT. Protease inhibitors: synthesis of bacterial collagenase and matrix metalloproteinase inhibitors incorporating arylsulfonylureido and 5-dibenzo-suberenyl/suberyl moieties. Bioorg Med Chem 2003; 11(10): 2227-39.
376. Fujisawa T, Odake S, Ogawa Y, Yasuda J, Morita Y, Morikawa T. Design and synthesis of sulfur based inhibitors of matrix metalloproteinase-1. Chem Pharm Bull (Tokyo) 2002; 50(2): 239-52.
377. Rosenblum G, Meroueh SO, Kleifeld O, et al. Structural basis for potent slow binding inhibition of human matrix metalloproteinase-2 (MMP-2). J Biol Chem 2003; 278(29): 27009-15.
378. Li J, Rush TS, 3rd, Li W, et al. Synthesis and SAR of highly selective MMP-13 inhibitors. Bioorg Med Chem Lett 2005; 15(22): 4961-6.
379. Churg A, Wang RD, Tai H, et al. Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-alpha release. Am J Respir Crit Care Med 2003; 167(8): 1083-9.
380. Fray MJ, Dickinson RP, Huggins JP, Occleston NL. A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem 2003; 46(16): 3514-25.
381. Auge F, Hornebeck W, Decarme M, Laronze JY. Improved gelatinase a selectivity by novel zinc binding groups containing galardin derivatives. Bioorg Med Chem Lett 2003; 13(10): 1783-6.
382. Ledour G, Moroy G, Rouffet M, et al. Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity. Bioorg Med Chem 2008; 16(18): 8745-59.
383. Hurst DR, Schwartz MA, Jin Y, et al. Inhibition of enzyme activity of and cell-mediated substrate cleavage by membrane type 1 matrix metalloproteinase by newly developed mercaptosulphide inhibitors. Biochem J 2005; 392(Pt 3): 527-36.
384. Hoffman A, Qadri B, Frant J, et al. Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis. J Med Chem 2008; 51(5): 1406-14.
385. Breuer E, Salomon CJ, Katz Y, et al. Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl-and cycloalkylcarbamoylphosphonic acids. J Med Chem 2004; 47(11): 2826-32.
386. Jacobsen FE, Lewis JA, Cohen SM. A new role for old ligands: discerning chelators for zinc metalloproteinases. J Am Chem Soc 2006; 128(10): 3156-7.
387. Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S. Synthesis and evaluation of novel oxazoline MMP inhibitors. Bioorg Med Chem Lett 2004; 14(19): 4935-9.
388. Reiter LA, Freeman-Cook KD, Jones CS, et al. Potent, selective pyrimidinetrione-based inhibitors of MMP-13. Bioorg Med Chem Lett 2006; 16(22): 5822-6.
389. Grams F, Brandstetter H, D'Alo S, et al. Pyrimidine-2,4,6-Triones: a new effective and selective class of matrix metalloproteinase inhibitors. Biol Chem 2001; 382(8): 1277-85.
390. Foley LH, Palermo R, Dunten P, Wang P. Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett 2001; 11(8): 969-72.
391. Kim SH, Pudzianowski AT, Leavitt KJ, et al. Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett 2005; 15(4): 1101-6.
392. Blagg JA, Noe MC, Wolf-Gouveia LA, et al. Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14. Bioorg Med Chem Lett 2005; 15(7): 1807-10.
393. Freeman-Cook KD, Reiter LA, Noe MC, et al. Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13. Bioorg Med Chem Lett 2007; 17(23): 6529-34.
394. Lein M, Jung K, Ortel B, et al. The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene 2002; 21(13): 2089-96.
395. Maquoi E, Sounni NE, Devy L, et al. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor. Clin Cancer Res 2004; 10(12 Pt 1): 4038-47.
396. Lewis EJ, Bishop J, Bottomley KM, et al. Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br J Pharmacol 1997; 121(3): 540-6.
397. Puerta DT, Lewis JA, Cohen SM. New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zincbinding groups. J Am Chem Soc 2004; 126(27): 8388-9.
398. Puerta DT, Cohen SM. Examination of novel zinc-binding groups for use in matrix metalloproteinase inhibitors. Inorg Chem 2003; 42(11): 3423-30.
399. Jacobsen FE, Lewis JA, Cohen SM. The design of inhibitors for medicinally relevant metalloproteins. ChemMedChem 2007; 2(2): 152-71.
400. Puerta DT, Griffin MO, Lewis JA, et al. Heterocyclic zinc-binding groups for use in next-generation matrix metalloproteinase inhibitors: potency, toxicity, and reactivity. J Biol Inorg Chem 2006; 11(2): 131-8.
401. Puerta DT, Mongan J, Tran BL, McCammon JA, Cohen SM. Potent, selective pyrone-based inhibitors of stromelysin-1. J Am Chem Soc 2005; 127(41): 14148-9.
402. Agrawal A, Romero-Perez D, Jacobsen JA, Villarreal FJ, Cohen SM. Zinc-binding groups modulate selective inhibition of MMPs. ChemMedChem 2008; 3(5): 812-20.
403. Yan YL, Cohen SM. Efficient synthesis of 5-amido-3-hydroxy-4-pyrones as inhibitors of matrix metalloproteinases. Org Lett 2007; 9(13): 2517-20.
404. Li JJ, Nahra J, Johnson AR, et al. Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. J Med Chem 2008; 51(4): 835-41.
405. Morales R, Perrier S, Florent JM, et al. Crystal structures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12. J Mol Biol 2004; 341(4): 1063-76.
406. Engel CK, Pirard B, Schimanski S, et al. Structural basis for the highly selective inhibition of MMP-13. Chem Biol 2005; 12(2): 181-9.
407. Dublanchet AC, Ducrot P, Andrianjara C, et al. Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors. Bioorg Med Chem Lett 2005; 15(16): 3787-90.
408. Gooljarsingh LT, Lakdawala A, Coppo F, et al. Characterization of an exosite binding inhibitor of matrix metalloproteinase 13. Protein Sci 2008; 17(1): 66-71.
409. Pochetti G, Montanari R, Gege C, Chevrier C, Taveras AG, Mazza F. Extra binding region induced by non-zinc chelating inhibitors into the S1' subsite of matrix metalloproteinase 8 (MMP-8). J Med Chem 2009; 52(4): 1040-9.
410. Johnson AR, Pavlovsky AG, Ortwine DF, et al. Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J Biol Chem 2007; 282(38): 27781-91.
411. Bernardo MM, Brown S, Li ZH, Fridman R, Mobashery S. Design, synthesis, and characterization of potent, slow-binding inhibitors that are selective for gelatinases. J Biol Chem 2002; 277(13): 11201-7.
412. Morrison JF, Walsh CT. The behavior and significance of slowbinding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol 1988; 61: 201-301.
413. Kruger A, Arlt MJ, Gerg M, et al. Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res 2005; 65(9): 3523-6.
414. Bonfil RD, Sabbota A, Nabha S, et al. Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor. Int J Cancer 2006; 118(11): 2721-6.
415. Bonfil RD, Dong Z, Trindade Filho JC, et al. Prostate cancerassociated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth. Am J Pathol 2007; 170(6): 2100-11.
416. Banke IJ, Arlt MJ, Mueller MM, et al. Effective inhibition of experimental metastasis and prolongation of survival in mice by a potent factor Xa-specific synthetic serine protease inhibitor with weak anticoagulant activity. Thromb Haemost 2005; 94(5): 1084-93.
417. Gu Z, Cui J, Brown S, et al. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci 2005; 25(27): 6401-8.
418. Lee M, Villegas-Estrada A, Celenza G, et al. Metabolism of a highly selective gelatinase inhibitor generates active metabolite. Chem Biol Drug Des 2007; 70(5): 371-82.
419. Celenza G, Villegas-Estrada A, Lee M, et al. Metabolism of (4-phenoxyphenylsulfonyl) methylthiirane, a selective gelatinase inhibitor. Chem Biol Drug Des 2008; 71(3): 187-96.
420. Lee M, Celenza G, Boggess B, et al. A potent gelatinase inhibitor with anti-tumor-invasive activity and its metabolic disposition. Chem Biol Drug Des 2009; 73(2): 189-202.
421. Nuti E, Tuccinardi T, Rossello A. Matrix metalloproteinase inhibitors: new challenges in the era of post broad-spectrum inhibitors. Curr Pharm Des 2007; 13(20): 2087-100.
422. Georgiadis D, Yiotakis A. Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge. Bioorg Med Chem 2008; 16(19): 8781-94.
423. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295(5564): 2387-92.
424. Renkiewicz R, Qiu L, Lesch C, et al. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum 2003; 48(6): 1742-9.
425. Chu QS, Forouzesh B, Syed S, et al. A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas. Invest New Drugs 2007; 25(4): 359-67.
426. Nomura S, Yoshimura K, Akiyama N, et al. HMG-CoA reductase inhibitors reduce matrix metalloproteinase-9 activity in human varicose veins. Eur Surg Res 2005; 37(6): 370-8.
427. Mannello F, Medda V, Ligi D, Raffetto JD. Glycosaminoglycan Sulodexide Inhibition of MMP-9 Gelatinase Secretion and Activity: Possible Pharmacological Role Against Collagen Degradation in Vascular Chronic Diseases. Curr Vasc Pharmacol 2012.
428. Mannello F, Raffetto JD. Matrix metalloproteinase activity and glycosaminoglycans in chronic venous disease: the linkage among cell biology, pathology and translational research. Am J Transl Res 2011; 3(2): 149-58.
429. Eming S, Smola H, Hartmann B, et al. The inhibition of matrix metalloproteinase activity in chronic wounds by a polyacrylate superabsorber. Biomaterials 2008; 29(19): 2932-40.
430. Vin F, Teot L, Meaume S. The healing properties of Promogran in venous leg ulcers. J Wound Care 2002; 11(9): 335-41.
431. Smeets R, Ulrich D, Unglaub F, Woltje M, Pallua N. Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration. Int Wound J 2008; 5(2): 195-203.
432. Schmutz JL, Meaume S, Fays S, et al. Evaluation of the nanooligosaccharide factor lipido-colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. Int Wound J 2008; 5(2): 172-82.
433. Mackelfresh J, Soon S, Arbiser JL. Combination therapy of doxycycline and topical tacrolimus for venous ulcers. Arch Dermatol 2005; 141(11): 1476-7.
434. Martens E, Leyssen A, Van Aelst I, et al. A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains. Biochim Biophys Acta 2007; 1770(2): 178-86.
435. Paemen L, Martens E, Masure S, Opdenakker G. Monoclonal antibodies specific for natural human neutrophil gelatinase B used for affinity purification, quantitation by two-site ELISA and inhibition of enzymatic activity. Eur J Biochem 1995; 234(3): 759-65.
436. Hu J, Van den Steen PE, Houde M, Ilenchuk TT, Opdenakker G. Inhibitors of gelatinase B/matrix metalloproteinase-9 activity comparison of a peptidomimetic and polyhistidine with single-chain derivatives of a neutralizing monoclonal antibody. Biochem Pharmacol 2004; 67(5): 1001-9.
437. Rao JS, Bhoopathi P, Chetty C, Gujrati M, Lakka SS. MMP-9 short interfering RNA induced senescence resulting in inhibition of medulloblastoma growth via p16(INK4a) and mitogen-activated protein kinase pathway. Cancer Res 2007; 67(10): 4956-64.
438. Jiang X, Dutton CM, Qi WN, Block JA, Garamszegi N, Scully SP. siRNA mediated inhibition of MMP-1 reduces invasive potential of a human chondrosarcoma cell line. J Cell Physiol 2005; 202(3): 723-30.
439. Currie JC, Fortier S, Sina A, Galipeau J, Cao J, Annabi B. MT1-MMP down-regulates the glucose 6-phosphate transporter expression in marrow stromal cells: a molecular link between pro-MMP-2 activation, chemotaxis, and cell survival. J Biol Chem 2007; 282(11): 8142-9.
440. Lakka SS, Gondi CS, Dinh DH, et al. Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas. J Biol Chem 2005; 280(23): 21882-92.
441. Bremer C, Tung CH, Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 2001; 7(6): 743-8.
442. Chen J, Tung CH, Mahmood U, et al. In vivo imaging of proteolytic activity in atherosclerosis. Circulation 2002; 105(23): 2766-71.
443. Milner JM, Cawston TE. Matrix metalloproteinase knockout studies and the potential use of matrix metalloproteinase inhibitors in the rheumatic diseases. Curr Drug Targets Inflamm Allergy 2005; 4(3): 363-75.
444. Mix KS, Coon CI, Rosen ED, Suh N, Sporn MB, Brinckerhoff CE. Peroxisome proliferator-activated receptor-gamma-independent repression of collagenase gene expression by 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and prostaglandin 15-deoxydelta(12,14) J2: a role for Smad signaling. Mol Pharmacol 2004; 65(2): 309-18.
445. Voils SA, Evans ME, Lane MT, Schosser RH, Rapp RP. Use of macrolides and tetracyclines for chronic inflammatory diseases. Ann Pharmacother 2005; 39(1): 86-94.
446. van der Laan WH, Quax PH, Seemayer CA, et al. Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3. Gene Ther 2003; 10(3): 234-42.
447. Krajnovic P. [Effect of a benzopyrone preparation in venous diseases during pregnancy]. Med Monatsschr 1977; 31(2): 86-8.
448. Shalinsky DR, Brekken J, Zou H, et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci 1999; 878: 236-70.
449. El-Bradey MH, Cheng L, Bartsch DU, Niessman M, El-Musharaf A, Freeman WR. The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinase, on a new animal model of epiretinal membrane. Retina 2004; 24(5): 783-9.
450. Garcia C, Bartsch DU, Rivero ME, et al. Efficacy of Prinomastat) (AG3340), a matrix metalloprotease inhibitor, in treatment of retinal neovascularization. Curr Eye Res 2002; 24(1): 33-8.
451. Ozerdem U, Mach-Hofacre B, Varki N, et al. The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on uveal melanoma rabbit model. Curr Eye Res 2002; 24(2): 86-91.
452. Foda HD, Rollo EE, Drews M, et al. Ventilator-induced lung injury upregulates and activates gelatinases and EMMPRIN: attenuation by the synthetic matrix metalloproteinase inhibitor, Prinomastat (AG3340). Am J Respir Cell Mol Biol 2001; 25(6): 717-24.
453. Price A, Shi Q, Morris D, et al. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin Cancer Res 1999; 5(4): 845-54.
454. Borkakoti N, Winkler FK, Williams DH, et al. Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor. Nat Struct Biol 1994; 1(2): 106-10.
455. Hu Y, Xiang JS, DiGrandi MJ, et al. Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Bioorg Med Chem 2005; 13(24): 6629-44.
456. Li W, Li J, Wu Y, et al. A selective matrix metalloprotease 12 inhibitor for potential treatment of chronic obstructive pulmonary disease (COPD): discovery of (S)-2-(8-(methoxycarbonylamino)dibenzo[b, d]furan-3-sulfonamido)-3-methylbu tanoic acid (MMP408). J Med Chem 2009; 52(7): 1799-802.
457. Michaelides MR, Dellaria JF, Gong J, et al. Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors. Bioorg Med Chem Lett 2001; 11(12): 1553-6.
458. Campestre C, Agamennone M, Tortorella P, et al. N-Hydroxyurea as zinc binding group in matrix metalloproteinase inhibition: mode of binding in a complex with MMP-8. Bioorg Med Chem Lett 2006; 16(1): 20-4.
459. Van Lint P, Wielockx B, Puimege L, Noel A, Lopez-Otin C, Libert C. Resistance of collagenase-2 (matrix metalloproteinase-8)-deficient mice to TNF-induced lethal hepatitis. J Immunol 2005; 175(11): 7642-9.
460. Biasone A, Tortorella P, Campestre C, et al. alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs. Bioorg Med Chem 2007; 15(2): 791-9.
461. Folgueras AR, Fueyo A, Garcia-Suarez O, et al. Collagenase-2 deficiency or inhibition impairs experimental autoimmune encephalomyelitis in mice. J Biol Chem 2008; 283(14): 9465-74.
462. Matziari M, Beau F, Cuniasse P, Dive V, Yiotakis A. Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11. J Med Chem 2004; 47(2): 325-36.
463. Romero-Perez D, Fricovsky E, Yamasaki KG, et al. Cardiac uptake of minocycline and mechanisms for in vivo cardioprotection. J Am Coll Cardiol 2008; 52(13): 1086-94.